Despite encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from PBMs. The insurers are typically erecting limitations to reimbursement, such as steep expense requirements and approval pro